era
rapid
global
frequent
travel
emerg
viral
infect
gain
immens
potenti
spread
unpreced
speed
scale
compar
past
pose
signific
challeng
coordin
intern
effort
global
surveil
infect
control
significantli
respiratori
viral
infect
spread
mostli
via
droplet
transmiss
extrem
contagi
caus
signific
morbid
mortal
outbreak
last
decad
molecular
diagnost
via
revers
transcriptas
polymeras
chain
reaction
rtpcr
key
rapid
diagnosi
viral
infect
howev
high
index
suspicion
earli
institut
appropri
isol
measur
remain
mainstay
control
contain
spread
viral
infect
although
treatment
viral
infect
remain
support
efficaci
antivir
agent
influenza
infect
exist
infect
discuss
chapter
includ
first
describ
middl
east
respiratori
syndrom
coronaviru
merscov
metapneumoviru
rhinoviru
c
well
describ
past
reemerg
last
decad
outbreak
result
signific
morbid
mortal
includ
adenoviru
influenza
viru
enteroviru
first
isol
california
rare
occasion
report
cluster
sinc
late
increasingli
report
variou
part
world
august
us
center
diseas
control
prevent
cdc
report
case
begin
midwest
case
report
state
etiolog
singlestrand
nonenvelop
rna
viru
belong
genu
enterovirus
famili
picornavirida
one
five
evd
serotyp
identifi
far
virolog
characterist
includ
abil
bind
sialic
acid
present
upper
respiratori
tract
facilit
respiratori
infect
era
rapid
global
frequent
travel
emerg
viral
infect
gain
immens
potenti
spread
unpreced
speed
scale
compar
past
pose
signific
challeng
coordin
intern
effort
global
surveil
infect
control
significantli
respiratori
viral
infect
spread
mostli
via
droplet
transmiss
extrem
contagi
caus
signific
morbid
mortal
outbreak
last
decad
molecular
diagnost
via
revers
transcriptas
polymeras
chain
reaction
rtpcr
key
rapid
diagnosi
viral
infect
howev
high
index
suspicion
earli
institut
appropri
isol
measur
remain
mainstay
control
contain
spread
viral
infect
although
treatment
viral
infect
remain
support
efficaci
antivir
agent
influenza
infect
exist
infect
discuss
chapter
includ
first
describ
middl
east
respiratori
syndrom
coronaviru
merscov
metapneumoviru
rhinoviru
c
well
describ
past
reemerg
last
decad
outbreak
result
signific
morbid
mortal
includ
adenoviru
influenza
viru
enteroviru
specif
diseas
howev
signific
number
patient
report
wheez
main
clinic
featur
patient
sever
respiratori
infect
present
tachypnea
retract
alreadi
mention
neurolog
symptom
includ
flaccid
myeliti
also
associ
infect
chest
radiograph
often
demonstr
peribronchi
thicken
infiltr
often
area
atelectasi
identifi
use
molecular
method
polymeras
chain
reaction
pcr
viral
cultur
fluid
sampl
nasopharynx
oropharynx
serum
commerci
avail
respiratori
multiplex
pcr
assay
may
abl
distinguish
enterovirus
rhinovirus
specif
assay
may
need
identifi
infect
clinic
suspicion
high
support
care
remain
mainstay
treatment
specif
treatment
current
avail
pleconaril
shown
effect
date
current
avail
vaccin
good
hand
hygien
prompt
diagnosi
subsequ
isol
case
main
approach
contain
spread
infect
initi
studi
suggest
patient
infect
compar
pulmonari
pathogen
rhinovirus
non
enterovirus
like
sever
respiratori
symptom
requir
hospit
howev
recent
retrospect
analysi
outbreak
st
loui
children
hospit
case
analyz
shown
signific
differ
sever
ill
patient
compar
viral
etiolog
may
due
ascertain
bia
sever
affect
children
test
thu
case
fatal
rate
appear
much
higher
probabl
realli
happen
number
respiratori
virus
includ
influenza
first
recogn
case
infect
support
care
recoveri
expect
day
fatal
associ
neurolog
complic
occasion
cardiac
event
middl
east
respiratori
syndrom
coronaviru
adult
infect
result
fever
well
upper
lower
respiratori
tract
symptom
includ
cough
breathless
rapidli
deterior
sever
acut
respiratori
distress
syndrom
symptom
myalgia
gastrointestin
symptom
diarrhea
vomit
abdomin
pain
commonli
present
howev
two
case
seri
middl
east
report
merscov
infect
ran
milder
cours
children
major
asymptomat
carrier
contact
symptomat
adult
case
sever
respiratori
symptom
occur
commonli
exist
comorbid
report
patient
age
rang
year
year
age
although
children
form
minor
case
may
due
limit
exposur
anim
health
care
set
infect
occur
respiratori
symptom
symptomat
case
rapidli
progress
median
time
onset
symptom
hospit
day
onset
intens
care
admiss
sever
case
approxim
day
complic
includ
acut
respiratori
failur
acut
respiratori
distress
syndrom
refractori
hypoxemia
extrapulmonari
complic
ischem
hepat
septic
shock
hypotens
acut
renal
failur
median
time
onset
death
day
patient
present
symptomat
merscov
infect
mainli
lower
respiratori
find
includ
tachypnea
rhonchi
retract
although
upper
respiratori
symptom
report
report
chest
xray
find
includ
unilater
bilater
patchi
opac
consolid
interstiti
infiltr
pleural
effus
laboratori
confirm
activ
merscov
infect
base
realtim
revers
transcript
pcr
rtpcr
detect
least
two
specif
genom
target
singl
posit
target
sequenc
second
target
confirm
nucleic
acid
sequenc
may
requir
epidemiolog
investig
origin
spread
diseas
specimen
collect
site
rtpcr
includ
lower
respiratori
sampl
bronchoalveolar
lavag
tracheal
sputum
aspir
upper
respiratori
sampl
nasopharyng
oropharyng
swab
well
serum
stool
specimen
although
highest
yield
respiratori
sampl
serolog
test
enzymelink
immunosorb
assay
elisa
immunofluoresc
assay
ifa
microneutr
assay
avail
detect
previou
infect
use
mainli
surveil
purpos
use
diagnost
tool
risk
crossreact
coronavirus
subsequ
import
case
report
european
countri
includ
franc
unit
kingdom
itali
germani
north
africa
tunisia
outbreak
sporad
case
nosocomi
outbreak
report
middl
east
larg
outbreak
occur
korea
guangdong
china
involv
case
death
sinc
accord
statist
world
health
organ
laboratoryconfirm
case
merscov
infect
includ
relat
death
merscov
envelop
singlestrand
rna
viru
belong
famili
coronavirida
coronavirus
reservoir
infect
thought
origin
anim
merscov
postul
origin
dromedari
camel
within
arabian
peninsula
molecular
isol
sever
alphacoronavirus
betacoronavirus
bat
saudi
arabia
part
world
suggest
involv
bat
human
infect
well
actual
rout
zoonot
transmiss
clearli
defin
despit
public
larg
casecontrol
studi
exact
pathogenesi
merscov
elucid
studi
look
ex
vivo
infect
hepatoma
cell
demonstr
sever
cytopath
effect
hock
colleagu
demonstr
spectral
microscopi
signific
merscov
antigen
express
type
ii
alveolar
cell
ciliat
bronchial
epithelium
uncili
cuboid
cell
termin
bronchiol
well
pulmonari
vessel
endotheli
cell
evid
alveolar
epitheli
damag
detach
type
ii
alveolar
epitheli
cell
associ
disrupt
tight
junction
chromatin
condens
nuclear
fragment
membran
bleb
seen
electron
microscopi
receptor
merscov
identifi
dipeptidyl
peptidas
exopeptidas
demonstr
cell
spectral
microscopi
merscov
infect
caus
signific
host
immun
dysregul
downregul
gene
involv
antigenpres
pathway
lead
subsequ
impair
adapt
immun
respons
possibl
explain
rapid
progress
ill
high
mortal
rate
merscov
infect
spread
via
travel
resid
countri
near
arabian
peninsula
infect
occur
via
droplet
transmiss
patient
close
contact
risk
persontoperson
transmiss
gener
low
superspread
event
identifi
similar
sever
acut
respiratori
syndrom
sar
coronaviru
singl
individu
associ
transmiss
larg
number
other
median
incub
period
secondari
case
humantohuman
transmiss
day
rang
day
least
age
year
although
common
childhood
respiratori
infect
immun
believ
transient
hmpv
infect
report
contribut
acut
respiratori
ill
elderli
age
comorbid
respiratori
condit
asthma
chronic
obstruct
pulmonari
diseas
condit
result
immunocompromis
statu
overal
rate
detect
hmpv
among
hospit
children
respiratori
studi
although
question
whether
hmpv
truli
pathogen
asymptomat
carriag
among
children
estim
hmpv
envelop
singlestrand
rna
viru
member
paramyxovirida
famili
belong
subfamili
pneumovirina
genu
metapneumoviru
two
genotyp
hmpv
exist
b
subgroup
base
fusion
f
attach
g
surfac
glycoprotein
pathogenesi
hmpv
infect
extens
studi
multipl
anim
model
studi
young
adult
cotton
rat
inocul
viru
demonstr
inflamm
within
surround
bronchi
bronchiol
signific
leukocytosi
hmpv
found
mostli
apic
surfac
columnar
cell
anim
model
upregul
mrna
relat
interferon
gamma
ifn
interleukin
il
demonstr
previou
infect
confer
partial
protect
rat
lower
viral
load
within
respiratori
tract
neutral
antibodi
respons
subsequ
infect
howev
longterm
immun
seem
unlik
given
incid
diseas
older
adult
hmpv
infect
transmit
via
close
direct
contact
contamin
secret
incub
period
hmpv
estim
day
durat
symptom
vari
accord
sever
commonli
less
week
howev
shed
viru
infect
case
last
week
acut
ill
viral
rna
found
stool
day
week
symptom
initi
larg
prospect
surveil
studi
done
us
cdc
hmpv
infect
children
found
infect
children
mostli
without
comorbid
younger
year
age
mani
infant
less
month
age
annual
rate
hospit
associ
hpmv
infect
similar
influenza
viru
per
lower
rsv
per
clinic
infect
hmpv
result
initi
upper
respiratori
tract
symptom
cough
rhinorrhea
fever
progress
lower
respiratori
tract
symptom
short
breath
wheez
sore
throat
conjunct
poor
appetit
rash
gastrointestin
symptom
vomit
diarrhea
report
singl
neg
result
recommend
specimen
sent
suffici
demonstr
activ
merscov
infect
accord
definit
us
cdc
howev
clinic
suspicion
remain
sampl
sent
falseneg
occur
patient
diagnos
merscov
consid
clear
activ
infect
deisol
two
consecut
specimen
test
neg
rtpcr
infecti
etiolog
present
similarli
acut
rapidli
progress
respiratori
distress
syndrom
includ
sar
influenza
viru
noninfect
caus
acut
respiratori
distress
syndrom
ard
consid
well
epidemiolog
histori
high
index
clinic
suspicion
critic
specif
antivir
develop
point
mainstay
treatment
remain
support
care
current
vaccin
avail
merscov
strict
infect
control
measur
includ
standard
contact
droplet
precaut
airborn
precaut
aerosolgener
procedur
must
taken
care
provid
suspect
confirm
case
shown
effect
control
nosocomi
outbreak
ksa
south
korea
continu
vigil
epidemiolog
surveil
good
hand
hygien
cough
etiquett
remain
mainstay
prevent
area
affect
outbreak
prognosi
guard
symptomat
case
especi
adult
everi
patient
report
die
number
children
infect
small
remain
seen
diseas
run
benign
cours
pediatr
age
group
adult
popul
patient
admit
intens
care
unit
mortal
rate
day
post
admiss
human
metapneumoviru
hmpv
first
isol
pediatr
patient
acut
respiratori
infect
netherland
subsequ
retrospect
serolog
studi
demonstr
presenc
antibodi
hmpv
human
year
prior
viru
sinc
found
worldwid
hmpv
account
viral
respiratori
tract
infect
occur
commonli
month
januari
april
unit
state
howev
recent
surveil
studi
unit
state
report
hmpv
season
occur
respiratori
syncyti
viru
rsv
influenza
season
serolog
studi
demonstr
children
europ
north
america
acquir
hmpv
infect
cytopath
effect
vitro
commonli
use
detect
techniqu
via
rtpcr
nasopharyng
oropharyng
sampl
direct
ifa
test
done
outbreak
set
shorter
turnaround
time
ifa
lower
sensit
serolog
test
use
mainli
epidemiolog
purpos
differenti
diagnos
similar
upper
respiratori
tract
present
would
includ
viral
etiolog
includ
rsv
influenza
parainfluenza
adenoviru
immunocompromis
host
lower
respiratori
tract
sign
fungal
etiolog
would
consid
well
treatment
hmpv
infect
like
viral
infect
mainli
support
howev
much
interest
develop
therapeut
option
ribavirin
nucleosid
inhibitor
licens
treatment
rsv
hepat
c
infect
demonstr
good
vitro
vivo
activ
hmpv
anim
model
antivir
fusion
inhibitor
also
current
investig
promis
treatment
option
includ
therapeut
antibodi
follow
success
introduct
monoclon
antibodi
palivizumab
rsv
infect
develop
specif
monoclon
antibodi
hmpv
ongo
exampl
antibodi
target
hmpv
fusion
protein
shown
therapeut
potenti
mous
model
anoth
exampl
intranas
administ
human
fab
standard
intraven
immunoglobulin
prepar
also
shown
inhibit
replic
hmpv
vitro
rna
interfer
new
approach
treat
rna
viral
infect
regul
gene
express
silenc
specif
mrna
two
extrem
effici
small
interf
rna
hmpv
identifi
deffrasn
colleagu
still
investig
phase
final
wyde
colleagu
investig
antivir
properti
sulfat
sialyl
lipid
heparin
found
activ
hmpv
vitro
although
yet
random
control
trial
therapeut
hmpv
infect
sever
case
uncontrol
studi
combin
oral
aerosol
ribavirin
polyclon
intraven
immunoglobulin
effect
effect
vaccin
hmpv
remain
develop
strateg
target
f
g
surfac
protein
live
attenu
inactiv
vaccin
develop
progress
particularli
challeng
fact
natur
infect
confer
transient
immun
reinfect
common
adulthood
rais
question
protect
effect
futur
vaccin
infect
control
remain
mainstay
prevent
especi
within
hospit
droplet
isol
infect
case
lower
respiratori
tract
symptom
implement
symptom
recoveri
although
children
infect
hmpv
higher
likelihood
supplement
oxygen
use
note
diagnosi
often
made
clinic
populationbas
prospect
surveil
studi
outpati
case
subsequ
found
posit
hmpv
discharg
mostli
diagnosi
viral
ill
bronchiol
inpati
case
mostli
discharg
diagnosi
bronchiol
asthma
pneumonia
although
infect
usual
mild
selflimit
studi
suggest
hmpv
infect
predispos
sever
bacteri
infect
complic
cours
diseas
clinic
find
infect
case
like
seen
respiratori
viral
infect
although
fever
less
common
children
hmpv
infect
influenza
one
studi
howev
find
respiratori
distress
tachypnea
wheez
common
patient
hmpv
infect
influenza
studi
initi
laboratori
find
may
reveal
lymphopenia
neutropenia
transamin
may
complet
normal
chest
xray
find
lower
respiratori
tract
involv
sever
diseas
especi
immunocompromis
demonstr
groundglass
opac
parenchym
airspac
consolid
illdefin
nodularlik
centrilobular
opac
bronchial
wall
thicken
fig
compar
rsv
pneumonia
one
seri
hmpv
pneumonia
show
asymmetr
find
diagnost
test
hmpv
infect
includ
variou
techniqu
cultur
nucleic
acid
amplif
test
naar
antigen
detect
serolog
test
cultur
viru
technic
challeng
owe
slow
growth
tracheal
epitheli
cell
increas
adher
streptococcu
pneumonia
coinfect
hrv
studi
also
demonstr
hrvexpos
macrophag
suboptim
respons
bacteri
tolllik
receptor
agonist
may
predispos
secondari
bacteri
infect
human
true
preval
pathogen
role
hrv
commun
investig
detail
hrv
found
lower
airway
fluid
cell
healthi
volunt
cohort
studi
though
shown
high
rate
hrvc
detect
hospit
children
lower
respiratori
ill
also
increas
data
link
wheez
secondari
hrv
earli
infanc
higher
risk
subsequ
develop
asthma
compar
wheez
caus
virus
childhood
origin
asthma
coast
studi
show
hrvrelat
wheez
first
year
life
led
threefold
risk
asthma
year
hrv
wheez
year
associ
pronounc
increas
asthma
risk
odd
ratio
hrvrelat
wheez
year
life
associ
even
dramat
increas
asthma
school
age
similar
birth
cohort
studi
australia
report
hrvrelat
wheez
infanc
associ
increas
asthma
risk
year
exact
mechan
hrv
trigger
contribut
inflammatori
chang
often
seen
asthma
unclear
suggest
evolv
combin
host
suscept
aeroallergen
sensit
abil
hrv
activ
proinflammatori
airway
remodel
pathway
symptom
hrvc
infect
typic
occur
incub
period
hour
diseas
spread
aerosol
droplet
transmiss
direct
persontoperson
contact
contamin
secret
symptom
gener
last
day
symptom
hrvc
infect
children
includ
fever
greater
upper
lower
respiratori
symptom
cough
wheez
short
breath
infect
commonli
associ
hrvc
includ
acut
upper
respiratori
tract
infect
acut
laryng
suppur
tonsil
otiti
media
bronchiti
bronchiol
bronchopneumonia
although
clinic
cours
gener
mild
hrvc
found
virul
hrva
run
sever
cours
immunocompromis
hostsfor
exampl
children
hematolog
malign
hematopoiet
stem
cell
transplant
recipi
longterm
steroid
use
common
find
hrvc
infect
includ
upper
respiratori
tract
sign
nasal
congest
cough
facial
tender
sinu
involv
inflamm
tympan
membran
otiti
media
lower
respiratori
tract
involv
symptom
wheez
cough
dyspnea
common
longer
intens
care
unit
icu
stay
compar
respiratori
infect
caus
rate
icu
admiss
intub
remain
similar
respiratori
infect
length
stay
hospit
significantli
differ
fatal
hmpv
infect
rare
human
rhinoviru
c
hrvc
newest
member
hrv
famili
discov
retrospect
sequenc
analysi
done
respiratori
sampl
patient
queensland
new
york
citi
show
distinct
cluster
known
hrva
hrvb
speci
shortli
describ
rhinovirus
quickli
report
worldwid
countri
includ
africa
asia
australia
america
europ
estim
contribut
greater
test
specimen
highlight
import
caus
respiratori
tract
infect
asia
unit
state
hrvc
hrva
preval
three
speci
appear
season
hrvc
infect
peak
incid
fall
winter
well
raini
season
tropic
countri
also
occur
throughout
year
hrvc
infect
predilect
young
infect
occur
children
less
year
age
especi
age
month
part
appar
rise
rhinoviru
c
infect
may
due
improv
viru
detect
method
led
increas
recognit
caus
sever
pneumonia
elderli
immunocompromis
specif
pediatr
oncolog
patient
undergon
hematopoiet
stem
cell
transplant
hrvc
positivesens
singlestrand
nonenvelop
rna
viru
picornavirida
famili
one
three
speci
hrv
base
phylogenet
sequenc
analysi
distinctli
distinguish
previous
describ
speci
hrva
hrvb
basi
genom
featur
healthi
individu
hrvc
infect
mostli
caus
rhinosinus
neutrophil
inflammatori
respons
result
increas
vascular
permeabl
mucu
hypersecret
upper
respiratori
tract
cough
though
less
common
thought
due
direct
infect
bronchi
irrit
posterior
pharyng
drainag
secret
patient
asthma
underli
lung
diseas
lower
respiratori
symptom
common
despit
fact
rhinovirus
grow
optim
favor
upper
respiratori
tract
postul
warmer
temperatur
lower
respiratori
tract
absolut
barrier
replic
mani
children
pneumonia
rhinovirus
isol
togeth
bacteri
pathogen
suggest
hrv
infect
may
lead
predisposit
respiratori
pathogen
support
studi
demonstr
human
despit
initi
report
high
mortal
rhinoviru
c
infect
case
associ
good
prognosi
recent
studi
hematolog
oncolog
patient
detect
death
associ
hrvc
infect
studi
philippin
although
rhinovirus
common
pathogen
identifi
children
hospit
pneumonia
fatal
associ
hrv
infect
unlik
influenza
adenoviru
recogn
pathogen
sinc
discoveri
howev
recent
interest
viru
emerg
accur
reemerg
respiratori
pathogen
aros
continu
small
outbreak
worldwid
unit
state
asia
affect
infant
young
children
age
month
significantli
taiwan
note
surg
case
trigger
establish
nation
surveil
system
found
acut
rise
adenovirusposit
respiratori
tract
specimen
baselin
peak
respiratori
virus
isol
outbreak
across
asia
appear
link
molecular
epidemiolog
although
mode
intern
spread
clear
adenovirus
icosahedr
nonenvelop
mediums
doublestrand
dna
virus
immunolog
distinct
serotyp
belong
famili
adenovirida
serotyp
link
epidem
keratoconjunct
includ
type
typic
caus
acut
respiratori
diseas
type
enter
adenovirus
children
mainli
type
adenovirus
known
resist
common
disinfect
remain
surfac
water
pool
lake
long
period
time
adenoviru
spread
droplet
transmiss
respiratori
secret
direct
contact
infect
secret
respiratori
urin
stool
ocular
viru
also
spread
water
via
fecalor
rout
shed
viru
stool
document
year
infect
shed
occur
urin
well
viru
caus
latent
infect
lymphoid
tissu
adenoid
tonsillar
tissu
throat
clinic
signific
unclear
incub
period
adenovir
infect
rang
day
infect
known
caus
pharyng
adenoid
tonsil
otiti
media
keratoconjunct
chest
xray
find
includ
increas
hazi
perihilar
lower
zone
region
fig
consolid
chang
pleural
effus
less
commonli
note
children
commonli
found
adult
patient
convent
method
viral
test
immunofluoresc
often
miss
presenc
hrvc
henc
recommend
gold
standard
diagnosi
hrvc
infect
molecular
test
rtpcr
nasopharyng
oropharyng
secret
coinfect
bacteri
infect
common
degre
rhinoviru
identif
asymptomat
individu
commun
known
henc
isol
rhinoviru
c
singl
sampl
lack
clinic
improv
time
may
requir
analysi
presenc
concomit
bacteri
pathogen
similar
common
viral
upper
respiratori
tract
pathogen
alreadi
mention
treatment
remain
support
symptomat
pleconaril
antivir
agent
known
effect
enteroviru
rhinoviru
infect
seem
option
sever
hrvc
infect
howev
owe
distinct
genom
differ
hrvc
compar
earlier
discov
hrva
like
hrvc
may
resist
drug
despit
signific
global
burden
rhinoviru
infect
vaccin
exist
point
antigen
heterogen
greater
rhinoviru
strain
strict
hand
hygien
droplet
precaut
patient
upper
respiratori
tract
symptom
remain
mainstay
prevent
detect
viru
perform
via
antigen
detect
pcr
viru
isol
serolog
antigen
test
direct
fluoresc
assay
respiratori
secret
nasopharyng
shown
sensit
specif
pcr
test
adenoviru
done
throat
swab
sputum
rectal
swab
report
sensit
respect
howev
pleural
effus
fluid
low
pickup
rate
adenoviru
estim
adenovir
pcr
blood
stool
sampl
use
immunocompromis
patient
case
sever
manifest
blood
serolog
test
demonstr
fourfold
rise
antibodi
titer
acut
convalesc
phase
goldstandard
diagnosi
less
commonli
done
owe
develop
rapid
diagnost
method
serotyp
routin
perform
use
mainli
epidemiolog
surveil
purpos
specif
treatment
exist
adenovir
infect
immunocompet
individu
infect
selflimit
immunocompromis
host
antivir
agent
cidofovir
use
treat
sever
infect
sever
novel
therapi
explor
treatment
postadenovir
bronchiol
obliteran
remain
larg
support
oxygen
supplement
bronchodil
corticosteroid
would
ideal
theoret
treatment
sinc
bronchiol
obliteran
larg
immunemedi
inflammatori
respons
mix
result
studi
children
use
system
steroid
adenovir
pneumonia
alter
progress
bronchiol
obliteran
case
seri
show
commonli
known
pharyngoconjunctiv
fever
lower
respiratori
tract
involv
pneumonia
bronchiti
also
seen
adenovir
infect
also
known
caus
extrapulmonari
manifest
commonli
seen
acut
gastroenter
acut
hemorrhag
cystiti
case
hepat
rare
meningoenceph
infect
particularli
sever
prolong
immunocompromis
especi
undergon
hematolog
stem
cell
transplant
certain
serotyp
particularli
report
result
epidem
fulmin
event
associ
longterm
respiratori
complic
bronchiol
obliteran
bronchiectasi
swyerjam
syndrom
bacteri
coinfect
patient
adenovir
infect
note
rare
minim
role
cours
diseas
sever
adenovir
infect
main
symptom
adenovir
infect
includ
fever
cough
rhinorrhea
sore
throat
bilater
conjunct
last
day
occasion
adenovir
infect
caus
prolong
fever
lower
respiratori
tract
involv
much
less
common
extrapulmonari
manifest
includ
diarrhea
abdomin
pain
vomit
hematuria
pharyngoconjunctiv
fever
typic
manifest
bilater
conjunct
inject
pharynx
tonsil
signific
bilater
cervic
lymphadenopathi
adenovir
pneumonia
find
includ
signific
hypoxia
wheez
featur
pulmonari
consolid
adenovir
infect
easili
confus
bacteri
infect
known
caus
leukocytosi
neutrophilia
peripher
blood
count
well
elev
inflammatori
marker
transamin
also
often
note
adenovir
infect
high
fever
prolong
viral
caus
children
adenovir
infect
often
presumpt
treat
bacteri
infect
blood
urin
cultur
antibiot
diagnosi
made
patient
lower
respiratori
tract
involv
chest
xray
find
typic
show
interstiti
pulmonari
infiltr
less
commonli
lobar
consolid
seen
fig
pharyngoconjunctiv
fever
adenovir
infect
mimic
viral
infect
common
differenti
inflammatori
condit
kawasaki
diseas
due
conjunctiv
involv
well
signific
cervic
lymphadenopathi
gastroenter
caus
adenovir
infect
similar
caus
virus
astroviru
noroviru
immunocompromis
patient
cytomegaloviru
epsteinbarr
viru
differenti
adenovir
enterocol
immunocompet
individu
recov
infect
sequela
howev
sever
case
adenovir
pneumonia
report
result
bronchiectasi
bronchiol
obliteran
death
sever
adenovir
lung
diseas
mostli
patient
major
underli
ill
immunocompromis
hematolog
transplant
patient
fatal
outcom
dissemin
adenovir
infect
liver
failur
respiratori
diseas
dissemin
infect
fatal
case
associ
particularli
serotyp
serotyp
also
report
associ
fatal
access
refer
list
onlin
expertconsultcom
possibl
clinic
benefit
intraven
methylprednisolon
treat
bronchiol
obliteran
limit
small
sampl
size
confound
bronchodil
therapi
larg
clinic
trial
effect
inhal
corticosteroid
treatment
bronchiol
obliteran
evid
suggest
latent
adenovir
infect
caus
eosinophil
airway
inflamm
lead
ineffect
steroid
treatment
militari
recruit
unit
state
routin
vaccin
adenoviru
due
occurr
outbreak
cessat
vaccin
case
becam
appar
new
oral
live
attenu
adenovir
vaccin
type
approv
use
militari
personnel
howev
vaccin
use
gener
public
